As part of an oral treatment regimen in ambulatory practice, certain uses in connection with drug consumption associated could alter treatment outcomes observed in randomized clinical trials. The increase in progression-free survival in myeloma may be accompanied by an impaired quality of life and a resurgence of pain symptoms over time, which could potentially lead to medication overuse involving painkillers but also psychotropic drugs. These combined consumption may affect survival through mechanisms of pharmacological or non-pharmacological interactions. As part of this project, we wish to explore the scheme of adherence to myeloma drugs, and thus validate the decision diagram of hypothesis of not adequate of drug use in ambulatory conditions, from observational data. This discrepancy could result from poor adherence or suboptimal drug use but also from concomitant exposures to other drugs which may interact with myeloma. Before considering a study of greater magnitude that could address the consequences of non optimal drug use on clinical response criteria, such as duration of response or survival, it seems appropriate to confirm these assumptions within ' an exploratory study.
Study Type
OBSERVATIONAL
Enrollment
236
Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
Evaluation of myeloma treatment observance in real life as assessed by data collected in french national system of information of health insurance
Time frame: Through the end of study (15 months)
Description deliverance scheme of treatment used in multiple myeloma as assessed by data collected in french national system of information of health insurance
Time frame: Through the end of study (15 months)
Evaluation of respect of official recommendation related to observance in multiple myeloma treatment as assessed by expression of Medication Possession Ratio (MPR)
The Medication Possession Ratio (MPR) measure compliance of prescriber with official recommendations and the one for the patient in relation to the prescription by evaluating the difference between the quantities delivered and the theoretical quantities calculated in joining recommended intake scheme. It is estimated by the ratio of number of defined daily doses delivered over a given period and the number of theoretical defined daily doses if maximum observance
Time frame: Through the end of study (15 months)
Description of care consumption in multiple myeloma as assessed by data collected in french national system of information of health insurance
Time frame: Through the end of study (15 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.